Duration of clopidogrel-based dual antiplatelet therapy and clinical outcomes after endeavor sprint zotarolimus-eluting stent implantation in patients presenting with acute coronary syndrome

Published: 4 July 2015
Author(s): Pil Sang Song, Joo-Yong Hahn, Doo-Il Kim, Young Bin Song, Seung-Hyuk Choi, Jin-Ho Choi, Dong Ryeol Ryu, Seung Ho Hur, Jin-Ok Jeong, Hun Sik Park, Hyo-Soo Kim, Hyeon-Cheol Gwon
Section: Original Article

The optimal duration of dual antiplatelet therapy (DAPT) remains controversial in patients with acute coronary syndrome (ACS). We sought to compare outcomes after the implantation of zotarolimus-eluting stent (ZES) between patients with ACS who received clopidogrel-based DAPT for >6months and those treated for ≤6months.